Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung Cancer

摘要: Study objective To contribute to the current debate about relative merits of meta-analysis literature (MAL) and individual patients data (MAP). Design Identification published randomized trials extraction essential results directly from reports. Setting Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Measurements Survival probability at 6 months after randomization, as estimated survival curves, has been considered end-point interest. Quality scoring studies also performed. Specific methodologic issues concerning estimation relevant quantities necessary for MAL have addressed. The pooled odds ratio death was 0.44, with 95 percent confidence interval 0.32 0.59, thus significantly favoring chemotherapy, it corresponds an increase median 3.9 best 6.7 chemotherapy. Conclusions our MAL, are line those a MAP recently published. However, they be light their actual clinical relevance balance between quality life, toxicity, costs chemotherapy care.